Salix Pharmaceuticals (SLXP)
Salix Pharmaceuticals Profit Margin: 5.82%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SLXP Profit Margin Rankings
| Overall | 54th percentile | 1979 of 4396 |
| Sector | 67th percentile | 152 of 470 in Healthcare |
| Industry | 41st percentile | 7 of 12 in Drugs - Generic |
SLXP Profit Margin Range, Past 5 Years
| Minimum | -70.06% | Mar 2008 |
| Maximum | 23.44% | Sep 2011 |
| Average | -10.59% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these SLXP related companies
SLXP News
Market Wrap Video + Additions to Watch List http://stks.co/442N including: $AH $LQDT $AMLN $PETM $SLXP
about 18 hours ago by StockTiger
about 18 hours ago by StockTiger
RT @StockTiger Market Wrap Video + Additions to Watch List http://stks.co/43sP including: $AH $LQDT $AMLN $PETM $SLXP
about 20 hours ago by sssc
about 20 hours ago by sssc
Market Wrap Video + Additions to Watch List http://stks.co/43h3 including: $AH $LQDT $AMLN $PETM $SLXP
about a day ago by StockTiger
about a day ago by StockTiger
Salix Pharmaceuticals to Present at Three Investment Conferences in June
May 29, 7:00AM Business Wire
May 29, 7:00AM Business Wire
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2012
May 18, 7:00AM Business Wire
May 18, 7:00AM Business Wire
RT @TraderFlorida $LNKD http://stks.co/3r1e Hanging tough $MNST $SLXP too
about 17 days ago by stockeye
about 17 days ago by stockeye
@Fibline Nice list yessir, liking $SLXP from last week, bought $ARIA today, like the divy on $PDLI, hope it breaks up
about 18 days ago by harmongreg
about 18 days ago by harmongreg
RS Gainers (20in5) $FE $XL $SLXP $D $CTL $TECH $PTEN $STUDY http://chart.ly/fu38dfn
about 22 days ago by gtlackey
about 22 days ago by gtlackey
What Do Willow Trees Have to Do with Pharmaceuticals | via @harmongreg http://stks.co/3jt9 $SLXP
about 24 days ago by STNet
about 24 days ago by STNet
What Do Willow Trees Have to Do with Pharmaceuticals? http://stks.co/3jXP via @harmongreg $SLXP
about 24 days ago by StockTwits
about 24 days ago by StockTwits
What Do Willow Trees Have to Do with Pharmaceuticals http://stks.co/3jVI $SLXP
about 24 days ago by harmongreg
about 24 days ago by harmongreg
Listen to $SLXP at deutsche bank ag health care conference - live at 04:10 PM, ondemand after - http://stks.co/3jEt
about 24 days ago by earningscast
about 24 days ago by earningscast
Auriga Reiterates a 'Hold' on Salix Pharmaceuticals (SLXP); Q1 Tops Estimates, But Upside Priced In
May 08, 10:47AM Street Insider
May 08, 10:47AM Street Insider
UPDATE: Jefferies Raises PT to $63 on Salix Pharmaceuticals; Q1 Beat and Raised Guidance
May 08, 7:34AM Benzinga
May 08, 7:34AM Benzinga
$RAX looks like that earnings play worked. $SLXP have to wait till tomorrow to see.
about 25 days ago by MaddStocks
about 25 days ago by MaddStocks
$SLXP Good buy area here at the $50 level. Several indicators showing a long entry here as it tries to regain the 50DMA>
about 30 days ago by IndianTrader
about 30 days ago by IndianTrader
Salix Pharmaceuticals to Present at Three Investment Conferences in May
May 01, 7:00AM Business Wire
May 01, 7:00AM Business Wire
FDA Extends PDUFA Date for Priority Review of NDA for Salix Pharma's (SLXP) Crofelemer Tablets
Apr 30, 2:15PM Street Insider
Apr 30, 2:15PM Street Insider
Salix Pharmaceuticals Announces Extension of Crofelemer NDA Priority Review
Apr 30, 2:13PM Business Wire
Apr 30, 2:13PM Business Wire
Salix (SLXP), Progenics (PGNX) Get FDA PDUFA Extension Date for RELISTOR
Apr 25, 8:01AM Street Insider
Apr 25, 8:01AM Street Insider
Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012
Apr 25, 8:00AM Business Wire
Apr 25, 8:00AM Business Wire
Salix Pharmaceuticals Announces 1Q2012 Financial Results Conference Call and Webcast
Apr 23, 7:00AM Business Wire
Apr 23, 7:00AM Business Wire
This tight channel after a significant sell off looks weak to me. Lower prices may be ahead. $SLXP http://chart.ly/j8vo9ed
about 46 days ago by TradetheLeaders
about 46 days ago by TradetheLeaders
Cantor Fitzgerald Maintains a 'Buy' on Salix Pharmaceuticals (SLXP); Suggests Buying Into Weakness
Apr 11, 8:22AM Street Insider
Apr 11, 8:22AM Street Insider
$SLXP lost 4% in heavy trade after brokerage Auriga downgraded the stock to hold from buy and lowered its price target to $51 from $54.
about 52 days ago by abubnic
about 52 days ago by abubnic
UPDATE - Auriga Downgrades Salix Pharma (SLXP) to Hold; Potential Limited on Relistor
Apr 10, 11:25AM Street Insider
Apr 10, 11:25AM Street Insider
Awsme RT @Sector_Trends: Weekly IBD group and sector rotation analysis posted http://stks.co/3G67 $QCOR $PRXL $WCG $CNC $SLXP $ACHN $VRX
about 55 days ago by purecharger
about 55 days ago by purecharger
Still holding 50DMA - not much to do until it either makes a new high or breaks the 50DMA $SLXP http://chart.ly/n7gxvgm
about 57 days ago by TradetheLeaders
about 57 days ago by TradetheLeaders
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SLXP | 51.43 | -0.38 | -0.73% | 3.079B |
| SLX | 40.95 | -1.00 | -2.38% | |
| SLW | 26.64 | +1.16 | +4.55% | 9.008B |
| VOXX | 9.56 | -0.30 | -3.04% | 205.19M |
| VOX | 62.61 | -1.55 | -2.42% | |
| VOOV | 55.76 | -1.81 | -3.14% | |
| VOG | 1.74 | -0.13 | -6.95% | 108.18M |
| VOD | 26.78 | -0.01 | -0.04% | 136.24B |
| VOCS | 15.72 | -0.41 | -2.54% | 327.12M |
| UTHR | 43.01 | -1.23 | -2.78% | 2.373B |